Switch theme
Sign up to access all valuation multiples
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
1999
316
LTM Revenue $104M
LTM EBITDA n/a
$99.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Agenus has a last 12-month revenue of $104M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Agenus achieved revenue of $103M and an EBITDA of -$101M.
Agenus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Agenus valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $156M | $103M | XXX | XXX | XXX |
| Gross Profit | -$99.2M | -$81.4M | XXX | XXX | XXX |
| Gross Margin | -63% | -79% | XXX | XXX | XXX |
| EBITDA | -$146M | -$101M | XXX | XXX | XXX |
| EBITDA Margin | -93% | -98% | XXX | XXX | XXX |
| Net Profit | -$220M | -$246M | XXX | XXX | XXX |
| Net Margin | -141% | -238% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Agenus's stock price is $2.
Agenus has current market cap of $45.0M, and EV of $99.5M.
See Agenus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $99.5M | $45.0M | XXX | XXX | XXX | XXX | $-8.83 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Agenus has market cap of $45.0M and EV of $99.5M.
Agenus's trades at 1.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Agenus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Agenus and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $99.5M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | -1.0x | XXX | XXX | XXX |
| P/E | -0.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAgenus's NTM/LTM revenue growth is 3%
Agenus's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Agenus's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Agenus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Agenus and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -34% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -98% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -31% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -95% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 69% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 69% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Agenus acquired XXX companies to date.
Last acquisition by Agenus was XXXXXXXX, XXXXX XXXXX XXXXXX . Agenus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Agenus founded? | Agenus was founded in 1999. |
| Where is Agenus headquartered? | Agenus is headquartered in United States of America. |
| How many employees does Agenus have? | As of today, Agenus has 316 employees. |
| Who is the CEO of Agenus? | Agenus's CEO is Dr. Garo H. Armen, PhD. |
| Is Agenus publicy listed? | Yes, Agenus is a public company listed on NAS. |
| What is the stock symbol of Agenus? | Agenus trades under AGEN ticker. |
| When did Agenus go public? | Agenus went public in 2000. |
| Who are competitors of Agenus? | Similar companies to Agenus include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Agenus? | Agenus's current market cap is $45.0M |
| What is the current revenue of Agenus? | Agenus's last 12-month revenue is $104M. |
| What is the current EV/Revenue multiple of Agenus? | Current revenue multiple of Agenus is 1.0x. |
| What is the current revenue growth of Agenus? | Agenus revenue growth between 2023 and 2024 was -34%. |
| Is Agenus profitable? | Yes, Agenus is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
